NCT00219596

Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension

An 8-Week, Randomized, Open-Label, Parallel Group Study Comparing The Efficacy And Safety Of Xalacom With The Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (planned)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

to compare efficacy and safety of Xalacom with the combination of unfixed Latanoprost and Timolol in subjects with open-angel glaucoma or ocular hypertension

Conditions

• Glaucoma, Open Angle
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Xalacom
DRUG	unfixed Latanoprost and Timolol

Timeline

• Start date: 2005-06-01
• Completion: 2006-09-01
• First posted: 2005-09-22
• Last updated: 2021-02-18

Locations

8 sites across 1 country: China